Form 4: Marinus Pharmaceuticals Director Ezickson Elan Disposes of Shares and Stock Options Following Merger Agreement

Director Ezickson Elan reports the disposal of common stock and stock options in Marinus Pharmaceuticals following the merger agreement with Immedica Pharma AB.

Summary

• Elan Ezickson, a director at Marinus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the disposal of 8,600 shares of common stock on February 7, 2025, at a price of $0.55 per share.
• Additionally, 2,300 shares underlying Restricted Stock Units (RSUs) were terminated.
• The transactions are related to the merger agreement between Marinus Pharmaceuticals and Immedica Pharma AB, where each share was acquired at $0.55.
• Out-of-the-money stock options were terminated without payment as per the merger agreement.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions related to a previously announced merger. There are no indications of unexpected positive or negative developments.

Negatives

• The director's stock options were terminated without any payment, indicating they were out-of-the-money at the time of the merger.

Future Outlook

The document does not contain forward-looking statements beyond the completion of the merger agreement.

Industry Context

This filing reflects the completion of a merger, a common event in the pharmaceutical industry where companies seek to consolidate resources, expand market reach, or acquire promising drug candidates.

Stakeholder Impact

• Shareholders received $0.55 per share as part of the merger agreement.
• Employees may experience changes as a result of the merger, although this is not detailed in the filing.

Key Dates

Keywords

Form 4, Marinus Pharmaceuticals, MRNS, Ezickson Elan, Immedica Pharma AB, Merger Agreement, Beneficial Ownership, Stock Options, Restricted Stock Units, Director